HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Abstract
The overlapping clinical features of Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB) make differentiation difficult in the clinical environment. Evaluating the CSF levels of biomarkers in AD and DLB patients could facilitate clinical diagnosis. CSF Visinin-like protein-1 (VILIP-1), a calcium-mediated neuronal injury biomarker, has been described as a novel biomarker for AD. The aim of this study was to investigate the diagnostic utility of CSF VILIP-1 and VILIP-1/Aβ1-42 ratio to distinguish AD from DLB. Levels of CSF VILIP-1, t-tau, p-tau181P , Aβ1-42 , and α-synuclein were measured in 61 AD patients, 32 DLB patients, and 40 normal controls using commercial ELISA kits. The results showed that the CSF VILIP-1 level had significantly increased in AD patients compared with both normal controls and DLB patients. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. Additionally, CSF VILIP-1 levels were positively correlated with t-tau and p-tau181P within each group and with α-synuclein in the AD and control groups. We conclude that CSF VILIP-1 could be a diagnostic marker for AD, differentiating it from DLB. The analysis of biomarkers, representing different neuropathologies, is an important approach reflecting the heterogeneous features of AD and DLB. Neuronal Ca(2+) -sensor protein VILIP-1 has been implicated in the calcium-mediated neuronal injury and pathological change of AD. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. CSF VILIP-1 is a useful biomarker for AD. Evaluating the CSF levels of VILIP-1 in AD and DLB patients could facilitate clinical diagnosis.
AuthorsXinni Luo, Le Hou, Haishan Shi, Xiaomei Zhong, Yufeng Zhang, Dong Zheng, Yan Tan, Guoyan Hu, Nan Mu, Jianping Chan, Xinru Chen, Yaxiu Fang, Fengchun Wu, Hongbo He, Yuping Ning
JournalJournal of neurochemistry (J Neurochem) Vol. 127 Issue 5 Pg. 681-90 (Dec 2013) ISSN: 1471-4159 [Electronic] England
PMID23800322 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 International Society for Neurochemistry.
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
  • MAPT protein, human
  • Neurocalcin
  • Peptide Fragments
  • SNCA protein, human
  • VSNL1 protein, human
  • alpha-Synuclein
  • amyloid beta-protein (1-42)
  • tau Proteins
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease (cerebrospinal fluid, diagnosis)
  • Amyloid beta-Peptides (cerebrospinal fluid)
  • Biomarkers (cerebrospinal fluid)
  • Cerebrospinal Fluid (metabolism)
  • Diagnosis, Differential
  • Female
  • Humans
  • Lewy Body Disease (cerebrospinal fluid, diagnosis)
  • Male
  • Middle Aged
  • Neurocalcin (cerebrospinal fluid)
  • Peptide Fragments (cerebrospinal fluid)
  • Plaque, Amyloid (cerebrospinal fluid, diagnosis)
  • ROC Curve
  • Sensitivity and Specificity
  • alpha-Synuclein (cerebrospinal fluid)
  • tau Proteins (cerebrospinal fluid)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: